ADAG

Adagene (ADAG)

Adagene Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ADAG

1 2 3 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/03/29	22 : 00	GlobeNewswire Inc.	Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update	NASDAQ:ADAG	Adagene Inc
2024/03/08	06 : 01	GlobeNewswire Inc.	Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board	NASDAQ:ADAG	Adagene Inc
2024/03/02	06 : 30	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:ADAG	Adagene Inc
2024/02/27	22 : 00	GlobeNewswire Inc.	Adagene to Present at the Leerink Partners Global Biopharma Conference 2024	NASDAQ:ADAG	Adagene Inc
2024/02/09	20 : 08	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ADAG	Adagene Inc
2024/02/09	20 : 00	GlobeNewswire Inc.	Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stab	NASDAQ:ADAG	Adagene Inc
2024/01/17	07 : 01	GlobeNewswire Inc.	Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)	NASDAQ:ADAG	Adagene Inc
2024/01/17	07 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ADAG	Adagene Inc
2024/01/04	19 : 00	GlobeNewswire Inc.	Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium	NASDAQ:ADAG	Adagene Inc
2023/11/04	01 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ADAG	Adagene Inc
2023/11/04	01 : 00	GlobeNewswire Inc.	Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023	NASDAQ:ADAG	Adagene Inc
2023/10/12	21 : 00	GlobeNewswire Inc.	Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting	NASDAQ:ADAG	Adagene Inc
2023/09/29	19 : 30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ADAG	Adagene Inc
2023/09/07	19 : 00	GlobeNewswire Inc.	Adagene to Present at Investor and Scientific Conferences in September	NASDAQ:ADAG	Adagene Inc
2023/08/31	20 : 32	GlobeNewswire Inc.	Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update	NASDAQ:ADAG	Adagene Inc
2023/08/31	20 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ADAG	Adagene Inc
2023/07/08	05 : 34	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ADAG	Adagene Inc
2023/05/04	22 : 01	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:ADAG	Adagene Inc
2023/05/04	22 : 00	GlobeNewswire Inc.	Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate	NASDAQ:ADAG	Adagene Inc
2023/04/28	20 : 06	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:ADAG	Adagene Inc
2023/04/28	20 : 03	Edgar (US Regulatory)	Annual and Transition Report (foreign Private Issuer) (20-f)	NASDAQ:ADAG	Adagene Inc
2023/04/28	20 : 00	GlobeNewswire Inc.	Adagene Announces Updates to its Board of Directors	NASDAQ:ADAG	Adagene Inc
2023/04/18	22 : 27	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:ADAG	Adagene Inc
2023/04/18	22 : 17	GlobeNewswire Inc.	Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors	NASDAQ:ADAG	Adagene Inc
2023/03/29	06 : 07	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:ADAG	Adagene Inc
2023/03/29	05 : 30	GlobeNewswire Inc.	Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update	NASDAQ:ADAG	Adagene Inc
2023/03/15	07 : 00	GlobeNewswire Inc.	Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April	NASDAQ:ADAG	Adagene Inc
2023/03/06	09 : 39	GlobeNewswire Inc.	Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board	NASDAQ:ADAG	Adagene Inc
2023/02/09	22 : 16	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:ADAG	Adagene Inc
2023/02/06	20 : 05	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:ADAG	Adagene Inc